BACKGROUND: The Dietary Approaches to Stop Hypertension (DASH) diet, which emphasizes fruits, vegetables, and low fat dairy products, significantly lowers blood pressure (BP). We conducted a clinical trial to assess the BP response to the DASH diet with an antihypertensive medication, losartan, in participants with essential hypertension. METHODS: A total of 55 hypertensive participants were randomly assigned to 8 weeks of controlled feeding with either a control diet or the DASH diet. Within each diet arm, participants received losartan 50 mg daily or placebo for 4 weeks each, in double blind, randomized, cross-over fashion. Twenty-four-hour ambulatory BP (ABP) was measured at the end of a 2-week run-in period (baseline) and after each 4-week intervention period. RESULTS: There was no significant change in ABP during the placebo period on the control diet (n = 28) (-2.3 +/- 1.5/-1.6 +/- 1.0 mm Hg), but there was a significant reduction in systolic ABP (-5.3 +/- 1.5 mm Hg, P <.05) and no change in DBP (-2.5 +/- 1.0 mm Hg) on the DASH diet (n = 27). Losartan significantly reduced ABP on the control diet (-6.7 +/- 1.5/-3.7 +/- 1.0 mm Hg, P <.05) and to a greater extent on the DASH diet (-11.7 +/- 1.5/-6.9 +/- 1.0 mm Hg, P <.05 versus basal and control diet) particularly in African Americans. On the DASH diet, DeltaSBP on losartan was inversely related to basal plasma renin activity (n = -0.53, P =.004). CONCLUSIONS: The DASH diet enhances the ABP response to losartan in essential hypertension. This effect is particularly marked in African Americans.
RCT Entities:
BACKGROUND: The Dietary Approaches to Stop Hypertension (DASH) diet, which emphasizes fruits, vegetables, and low fat dairy products, significantly lowers blood pressure (BP). We conducted a clinical trial to assess the BP response to the DASH diet with an antihypertensive medication, losartan, in participants with essential hypertension. METHODS: A total of 55 hypertensiveparticipants were randomly assigned to 8 weeks of controlled feeding with either a control diet or the DASH diet. Within each diet arm, participants received losartan 50 mg daily or placebo for 4 weeks each, in double blind, randomized, cross-over fashion. Twenty-four-hour ambulatory BP (ABP) was measured at the end of a 2-week run-in period (baseline) and after each 4-week intervention period. RESULTS: There was no significant change in ABP during the placebo period on the control diet (n = 28) (-2.3 +/- 1.5/-1.6 +/- 1.0 mm Hg), but there was a significant reduction in systolic ABP (-5.3 +/- 1.5 mm Hg, P <.05) and no change in DBP (-2.5 +/- 1.0 mm Hg) on the DASH diet (n = 27). Losartan significantly reduced ABP on the control diet (-6.7 +/- 1.5/-3.7 +/- 1.0 mm Hg, P <.05) and to a greater extent on the DASH diet (-11.7 +/- 1.5/-6.9 +/- 1.0 mm Hg, P <.05 versus basal and control diet) particularly in African Americans. On the DASH diet, DeltaSBP on losartan was inversely related to basal plasma renin activity (n = -0.53, P =.004). CONCLUSIONS: The DASH diet enhances the ABP response to losartan in essential hypertension. This effect is particularly marked in African Americans.
Authors: Laura P Svetkey; Emily L Harris; Eden Martin; William M Vollmer; Gayle T Meltesen; Vincent Ricchiuti; Gordon Williams; Lawrence J Appel; George A Bray; Thomas J Moore; Michelle P Winn; Paul R Conlin Journal: Am J Hypertens Date: 2010-11-18 Impact factor: 2.689
Authors: Bei Sun; Jonathan S Williams; Laura P Svetkey; Nikheel S Kolatkar; Paul R Conlin Journal: Am J Clin Nutr Date: 2010-06-02 Impact factor: 7.045
Authors: Christina D Filippou; Costas P Tsioufis; Costas G Thomopoulos; Costas C Mihas; Kyriakos S Dimitriadis; Lida I Sotiropoulou; Christina A Chrysochoou; Petros I Nihoyannopoulos; Dimitrios M Tousoulis Journal: Adv Nutr Date: 2020-09-01 Impact factor: 8.701
Authors: James A Blumenthal; Andrew Sherwood; Patrick J Smith; Stephanie Mabe; Lana Watkins; Pao-Hwa Lin; Linda W Craighead; Michael Babyak; Crystal Tyson; Kenlyn Young; Megan Ashworth; William Kraus; Lawrence Liao; Alan Hinderliter Journal: Am Heart J Date: 2015-08-14 Impact factor: 4.749
Authors: Shirley R Craddick; Patricia J Elmer; Eva Obarzanek; William M Vollmer; Laura P Svetkey; Martha C Swain Journal: Curr Atheroscler Rep Date: 2003-11 Impact factor: 5.113